YouthBio develops precision gene therapies utilizing partial cellular reprogramming to address neurodegenerative conditions like Alzheimer's disease. Their approach targets the epigenetic root of these disorders, aiming for disease reversal through a single injection activated by an oral pill. The company focuses on translating Nobel Prize-winning science into clinical treatments for significant unmet needs in brain health.
Funding
Funding not disclosed
Founders
Product
Problem
Age-related brain diseases, such as Alzheimer's, lead to cognitive decline due to the degradation of neuronal and glial cells. Current treatments offer limited efficacy in restoring youthful gene expression and improving overall cognitive function in affected individuals.
Solution
YouthBio Therapeutics develops tissue-specific gene therapies leveraging partial cellular reprogramming to rejuvenate cells and restore a more youthful gene expression profile. The company focuses on targeting key organ systems, starting with single-organ therapies aimed at brain diseases like Alzheimer's. By reprogramming neuronal and glial cells, YouthBio aims to improve cognitive function and potentially delay or reverse age-related cognitive decline. Their approach seeks to address the underlying causes of aging at the cellular level, offering a potential path towards systemic rejuvenation.
Target Audience
The primary target audience includes individuals affected by age-related cognitive decline and brain diseases like Alzheimer's, as well as healthcare providers and researchers in the field of regenerative medicine.
Features
- Tissue-specific gene therapies targeting neuronal and glial cells
- Partial cellular reprogramming to restore youthful gene expression
- Focus on brain diseases such as Alzheimer's
- Aims to improve cognitive function and delay age-related cognitive decline